关于控股股东、持股5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股东股份质押基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2025-055 恩威医药股份有限公司 ■ 上述股东及其一致行动人累计质押股份数量占其所持公司股份数量比例超过50%，现就相关情况说明如 下： 1、本次股份质押不用于满足上市公司生产经营需求； 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为14,140,836股，占其所持公司股份的 19.89%，占公司总股本的13.74%，对应融资余额为16,000万元；未来一年内到期的累计质押股份数量为 54,420,836 股，占其所持公司股份的76.54%，占公司总股本的52.89%，对应融资余额为55,600万元。公 司及其一致行动人具备相应的资金偿还能力，还款资金来源为自有及自筹资金。 3、截至本公告披露日，上述股东及其一致行动人不存在非经营性资金占用、违规担保等侵害上市公司 利益的情形； 4、上述股东及其一致行动人股 ...

Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [2][6] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [4] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility [6] Company Developments - The new production line will increase the company's total liquid preparation production capacity to 240 million bottles annually, with a maximum daily capacity of 800,000 bottles [2] - Key equipment upgrades include a new water bath sterilizer with a 42.8% increase in capacity and an AI-driven automatic light inspection machine for optimized detection parameters [6] - The company is advancing its "smart production line" initiative, focusing on data integration across the entire supply chain from planting to production and consumption [6] Market Trends - The main categories driving the market include medications for respiratory diseases, tonics for energy and blood, and digestive system diseases [4] - Tongrentang Technology's oral liquid products, such as Shenmai Drink and Children's Cough Syrup, are gaining traction due to their quick efficacy, precise dosing, and ease of use, aligning with modern consumer demands [4]

Core Insights - Tongrentang Technology has made significant progress in the capacity layout of liquid preparations, with the new oral liquid production line expected to submit GMP compliance inspection application by the end of the year [1] - The market for traditional Chinese medicine liquid preparations, including oral liquids, has seen continuous growth, with sales exceeding 20 billion yuan in 2023 and expected to maintain stable growth in 2024 [3] - The company has established a closed-loop production system suitable for continuous production of traditional Chinese medicine, enhancing production efficiency and flexibility in response to market demands [6] Group 1 - The new production line will increase the company's total capacity to four liquid preparation lines, with a maximum daily output of 800,000 bottles and an annual designed capacity exceeding 240 million bottles [1] - Key product categories driving market growth include medications for respiratory diseases, tonics, and digestive system diseases, with Tongrentang's oral liquid products benefiting from their quick efficacy and ease of use [3] - The introduction of advanced equipment, such as a new water bath sterilizer with a 42.8% increase in capacity and AI-enhanced automatic inspection machines, will further optimize production processes [6] Group 2 - The company is advancing its "smart production line" initiative, integrating data across the entire supply chain from cultivation to production, distribution, and consumption [6] - The deployment of a visual "cockpit" system in the workshop allows for real-time monitoring of production progress and key milestones, supporting resource utilization and cost control [6] - By embedding technological innovation into its operations, Tongrentang Technology aims to strengthen its competitive advantage in the modern traditional Chinese medicine sector, enhancing product innovation and operational efficiency [6]

Core Viewpoint - The Beijing International Intangible Cultural Heritage Week showcased traditional Chinese medicine practices, particularly the handmade production of Tong Ren Tang's An Gong Niu Huang Wan, highlighting the importance of cultural heritage in modern health practices [1][11]. Group 1: Event Highlights - The event featured a live demonstration of the traditional production techniques of An Gong Niu Huang Wan by Kong Lingjun, a master craftsman, allowing attendees to experience the charm of traditional Chinese medicine [1][11]. - The exhibition included a variety of Tong Ren Tang's major traditional Chinese medicine products, such as Liu Wei Di Huang Wan and Qian Bei Pi Pa Tang, providing visitors with comprehensive health information for the autumn season [9]. Group 2: Audience Engagement - Attendees expressed curiosity and eagerness to participate in the hands-on experience of making medicinal pills, with many finding the process more challenging than expected [5][7]. - Children showed particular interest in the pill-making process, with parents supporting their engagement in traditional culture through hands-on learning experiences [7]. Group 3: Craftsmanship and Training - Kong Lingjun emphasized the importance of skill and precision in the pill-making process, noting that mastering the technique requires at least three years of training to meet GMP standards [11]. - The company focuses on the transmission and development of traditional craftsmanship, ensuring that the skills are passed down to future generations through practical training [11].

Core Viewpoint - Beijing Tongrentang Technology Development Co., Ltd. showcased traditional Chinese medicine at the 2025 China Open Tennis Tournament, blending ancient practices with modern health concepts to attract a younger audience [1][12]. Group 1: Product Showcase - The exhibition featured a variety of traditional Chinese medicine products, including Shengmai Drink, Liuwei Dihuang Wan, and Jingshi Niuhuang Jiedu Pian, highlighting the company's strong foundation in traditional medicine [3]. - A range of health products was also presented, such as health drinks, skincare masks, and hair care products, aligning with the health-oriented philosophy of the event [5]. Group 2: Engagement with Athletes - Notable tennis player Sorana Cirstea participated in a hands-on experience of making herbal sachets, demonstrating the interactive approach of the exhibition [8][10]. - The company aims to enhance global recognition of traditional Chinese medicine through athlete involvement and innovative presentations [12]. Group 3: Scent Products - The company introduced its "Bencao Zhi Yue" series and other aromatic products at the player’s banquet, which became a popular attraction among attendees [13][16]. - The scent products are developed based on the concept of "medicinal fragrance," with nearly 140 products available, focusing on benefits like sleep aid and relaxation [18]. Group 4: Market Expansion - The products were also made available in 16 authorized cultural and creative stores during the event, expanding the reach of Tongrentang's offerings to a broader audience [21].

Core Viewpoint - The event organized by Beijing Tongrentang Technology Development Co., Ltd. focuses on addressing the health concerns of office workers through traditional Chinese medicine solutions, emphasizing the integration of health awareness into daily work life [1][7][13] Group 1: Health Issues and Solutions - Common health issues faced by office workers include acne from spicy food, fatigue from long hours, and emotional stress due to work pressure [2][5] - The company offers targeted products to address these specific health concerns, such as Jingzhi Niuhuang Jiedu Pian for heat relief, Huoxiang Zhengqi Shui for summer discomfort, and Ren Dan for boosting energy [5][9] Group 2: Event Engagement and Experience - The event featured interactive sessions where employees could learn about the products in relatable scenarios, enhancing their understanding and engagement [11][13] - The presence of experienced traditional Chinese medicine experts provided personalized consultations, addressing common issues like fatigue and stress-related insomnia [9][11] Group 3: Brand Trust and Community Building - The event aimed to build trust in the brand by allowing employees to experience the products firsthand, leading to positive word-of-mouth and potential repeat purchases [7][13] - The interactive and fun atmosphere of the event helped to foster a proactive approach to health among employees, making health knowledge more accessible and engaging [11][13] Group 4: Future Directions - The company plans to continue exploring ways to integrate traditional Chinese medicine into modern lifestyles, focusing on various workplace scenarios and health needs [13] - By leveraging technology and maintaining a caring approach, the company aims to keep traditional Chinese medicine relevant and beneficial for contemporary health challenges [13]

Core Insights - The demand for summer heat-relief products has surged since July, with companies like Beijing Tongrentang Technology Development Co., Ltd. ramping up production of traditional remedies such as Ren Dan and Huo Xiang Zheng Qi Shui to meet market needs [1][3] Group 1: Product Development and Production - The company has adjusted its production capacity and efficiency to ensure timely supply of summer health products, including increasing staffing for summer medication production [1] - Modern and intelligent equipment has been integrated into the production process, such as the introduction of centrifugal coating granulators for standardized management of production processes [3] - Six types of summer health products, including Ren Dan and Huo Xiang Zheng Qi Shui, have been fully distributed to pharmacies nationwide, ensuring consumer safety and health during the summer [3] Group 2: Product Features and Benefits - Ren Dan is designed to alleviate discomfort caused by high temperatures, utilizing ingredients like menthol and borneol to provide a cooling effect [7] - Huo Xiang Zheng Qi Shui addresses issues related to heat and humidity, using a classic formula that includes Huo Xiang as the main ingredient to relieve symptoms like headaches and gastrointestinal discomfort [5] - Sheng Mai Yin serves as an energy supplement for those who sweat excessively in summer, featuring ingredients like red ginseng and wheat to nourish and hydrate [9]

Core Insights - In Q1 2025, Tongrentang Technology Company focused on market demand, enhancing product variety and channel development to stimulate marketing momentum [1] Group 1: Product Strategy - The company emphasized "focusing" on major products, directing promotional resources towards key varieties such as Yao Medicine 300 Years, Ejiao, and children's medicine, creating a clear product structure [1] - Core products like Xihuang Pill, Jingzhi Niuhuang Jiedu Pian, and Liuwuwei Dihuang Wan series have optimized pricing systems and operational strategies, achieving coverage in over 30 provinces [9] Group 2: Marketing Initiatives - The "Flag Planting Action" marketing campaign covered 10 key provinces, conducting 206 events and nearly 1500 terminal promotion activities, successfully enhancing product shelf presence and awareness [9] - The company targeted younger audiences with innovative marketing strategies, such as the "Beijing Tongrentang Super Good Pill" campaign during the JD Super Brand Day, appealing to their health-conscious yet skeptical mindset [11] Group 3: Community Engagement - The company engaged in community education about product knowledge, leveraging events like the Winter Olympics to promote health trends, particularly in Harbin [11][14] - Creative marketing slogans and campaigns, such as the AI-themed short films, resonated with younger demographics, making products like Jingzhi Niuhuang Jiedu Pian and Ejiao popular during the spring health season [12][14]

Core Viewpoint - Tongrentang Technology reported a revenue of 7.26 billion and a net profit of 0.887 billion for the fiscal year 2024, demonstrating resilience in a challenging pharmaceutical market environment [1] Group 1: Financial Performance - The company achieved a revenue of 7.26 billion and a net profit of 0.887 billion during the reporting period [1] - Despite challenges such as rising raw material prices and decreased foot traffic in stores, the company improved its overall operational quality [1] Group 2: Innovation and R&D - Tongrentang Technology increased its investment in research and development, accelerating the development of innovative drugs and classic formulas [2] - The company received clinical trial approval for Qishen Granules, marking its first clinical approval for a traditional Chinese medicine in eight years [2] - Several products underwent pharmacological mechanism studies, enhancing their market competitiveness and clinical recognition [2] Group 3: Market Strategy and Product Expansion - In response to external challenges, the company adjusted its market strategy, focusing on channel management, price stability, and terminal empowerment [3] - The company launched promotional activities for its "Yuyao 300" product line, resulting in nine products exceeding 0.1 billion in sales [3] Group 4: Channel Development - Tongrentang Technology strengthened its partnerships with major distributors and conducted over 450 promotional events in previously untapped markets [4] - The company aimed to enhance product distribution rates and terminal effectiveness through targeted market strategies [4] Group 5: Risk Management and Future Plans - The company plans to enhance its governance and core competitiveness to address risks and challenges [5] - Future initiatives include a new round of collaborative innovation in traditional Chinese medicine, aiming to complete clinical research on five products by 2025 [5]